DENVER, Nov. 24, 2008 (GLOBE NEWSWIRE) -- The law firm of Dyer & Berens LLP (www.DyerBerens.com) announced today that it has initiated an investigation concerning losses suffered by investors who purchased the common stock of KV Pharmaceutical Company (NYSE:KV-A) (NYSE:KV-B) between February 15, 2008 and November 12, 2008. The investigation concerns whether the company may have made materially false and misleading statements about its compliance with federal regulations concerning the manufacture and marketing of certain generic drug products as well as its financial prospects.
If you have information relevant to the investigation, or if you believe you were harmed by potentially false or misleading statements of the company, you may contact Jeffrey A. Berens, Esq. at (888) 300-3362 or via email at jeff@dyerberens.com.
The law firm of Dyer & Berens LLP focuses on complex class action litigation on behalf of injured investors throughout the nation. The firm's extensive experience in securities litigation, particularly in cases brought under the Private Securities Litigation Reform Act, has contributed to the recovery of hundreds of millions of dollars for aggrieved investors. For more information about the firm, please go to www.DyerBerens.com.